Restasis (Cyclosporine Ophthalmic Emulsion) 0.05% w/v

What Is Restasis?

Restasis is an ophthalmic emulsion formulated with cyclosporine 0.05% w/v, an immunomodulatory and anti-inflammatory agent. It is indicated for patients experiencing chronic dry eye disease (keratoconjunctivitis sicca), particularly where tear production is suppressed by inflammation of the lacrimal glands and ocular surface tissues.

Unlike over-the-counter lubricating eye drops, which provide short-lived symptomatic relief, Restasis addresses the underlying inflammatory mechanism contributing to reduced tear secretion. This makes it a cornerstone long-term therapy in appropriate patients diagnosed with moderate to severe dry eye disease.

Chronic dry eye disease is recognised by the NHS guidance on dry eye as a multifactorial condition involving tear film instability and ocular surface inflammation. Immunomodulatory treatments such as topical ciclosporin are recommended in persistent cases under specialist supervision.

How Restasis Works

The active substance, ciclosporin, works by modulating immune activity at the ocular surface. In dry eye disease, inflammatory pathways involving activated T-lymphocytes contribute to impaired lacrimal gland function and epithelial damage.

Restasis inhibits T-cell activation and reduces the release of pro-inflammatory cytokines. By suppressing this inflammatory cascade, the medication helps restore the eye’s natural ability to produce tears. Over time, this can improve tear volume, stabilise the tear film, and reduce ocular surface damage.

Clinical literature has demonstrated that topical ciclosporin can significantly improve objective markers of tear production and ocular surface integrity in appropriately selected patients. Regulatory and safety oversight for medicines containing ciclosporin in the UK and Europe is provided by bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA).

Indications and Suitable Patients

Restasis is recommended for adults diagnosed with moderate to severe dry eye disease where tear production is reduced due to inflammation. It may be particularly beneficial for individuals who experience:

• Persistent dryness or grittiness
• Ocular burning or stinging
• Redness and irritation
• Fluctuating or blurred vision related to tear instability
• Symptoms unresponsive to artificial tears alone

Treatment should only be initiated following assessment by a qualified healthcare professional. A confirmed diagnosis ensures that immunomodulatory therapy is clinically appropriate.

Available Packaging Options

Single-Use Preservative-Free Vials

Each single-use vial contains 0.4 mL of Restasis ophthalmic emulsion and is designed for one-time administration. These preservative-free units minimise the risk of contamination and are suitable for patients who are sensitive to preservatives.

• Available in trays of 30 or 60 vials
• Intended for single application before disposal
• Convenient for travel and controlled dosing

Multidose Bottle

The multidose presentation incorporates a specialised filtration system that maintains sterility across repeated uses. This format may be preferred by long-term users seeking a more environmentally conscious and cost-effective option.

• Designed for repeated dosing
• Advanced filter mechanism to preserve sterility
• Practical for ongoing daily treatment

Dosage and Administration

Restasis should be used exactly as prescribed. The standard recommended dosage is:

• Instil one drop into each affected eye twice daily
• Administer approximately 12 hours apart

Step-by-Step Instructions

1. Wash hands thoroughly before use.
2. Gently shake the vial or bottle to ensure uniform mixing of the emulsion.
3. Tilt the head backwards and instil one drop into the lower conjunctival sac.
4. Avoid allowing the dropper tip to contact the eye or surrounding surfaces.
5. If using artificial tears, wait at least 15 minutes before or after application.
6. Remove contact lenses prior to administration and reinsert after 15 minutes.

Continued adherence is essential, as therapeutic benefit may take several weeks to become noticeable.

Key Benefits of Restasis

• Clinically demonstrated improvement in natural tear production
• Targets inflammatory pathways underlying chronic dry eye
• Supports restoration of ocular surface health
• Preservative-free formulation (single-use format)
• Suitable for long-term management under medical supervision

By addressing inflammation rather than simply lubricating the eye, Restasis provides a disease-modifying approach to chronic dry eye management.

Possible Side Effects

As with all medicines, side effects may occur. Frequently reported adverse effects include:

• Transient burning sensation upon instillation
• Eye redness
• Blurred vision immediately after application
• Foreign body sensation

Most reactions are mild and temporary. If symptoms persist or worsen, medical advice should be sought promptly.

Pregnancy and Breastfeeding

Data on the use of topical ciclosporin during pregnancy are limited. Although systemic absorption from ophthalmic administration is minimal, Restasis should only be used during pregnancy if the anticipated benefits outweigh potential risks.

Breastfeeding mothers should consult their healthcare professional before use to determine suitability.

Storage Instructions

• Store at room temperature between 15°C and 25°C.
• Keep in original packaging until use.
• Do not freeze.
• Ensure bottle caps are securely replaced after use.

Why Purchase Restasis Online?

Purchasing Restasis online from a regulated pharmacy may provide cost savings while maintaining pharmaceutical quality standards. Competitive pricing structures can make long-term dry eye management more affordable.

Patients are encouraged to ensure that any online pharmacy is properly regulated and requires a valid prescription before dispensing medication.

Further Reading

For comprehensive prescribing information, consult the official product documentation: Restasis Product Monograph (AbbVie).